F-Star Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>FT</div>
FSTX -- USA Stock  

USD 8.46  0.18  2.08%

F-Star Therapeutics is currently generating 12.3325% in daily expected returns and assumes 15.7606% risk (volatility on return distribution) over the 60 days horizon. As many old-fashioned traders are trying to avoid healthcare space, it makes sense to break down F-Star Therapeutics a little further and try to understand its current volatility patterns. We will inspect how risky is to take a position in F-Star Therapeutics at this time.
Published over a month ago
View all stories for F-Star Therapeutics | View All Stories
Will F Star Therapeutics (NASDAQ:FSTX) slide in December?
F-Star Therapeutics holds a performance score of 54 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -0.3737, which means possible diversification benefits within a given portfolio. Let's try to break down what F-Star's beta means in this case. As returns on the market increase, returns on owning F-Star Therapeutics are expected to decrease at a much lower rate. During the bear market, F-Star Therapeutics is likely to outperform the market. Although it is essential to pay attention to F-Star Therapeutics historical returns, it is also good to be reasonable about what you can do with equity current trending patterns. Our philosophy in predicting future potential of any stock is to look not only at its past charts but also at the business as a whole, including all available fundamental and technical indicators. To evaluate if F-Star Therapeutics expected return of 12.33 will be sustainable into the future, we have found twenty-eight different technical indicators, which can help you to check if the expected returns are sustainable. Use F-Star Therapeutics potential upside, as well as the relationship between the accumulation distribution and price action indicator to analyze future returns on F-Star Therapeutics.
Volatility is a rate at which the price of F-Star Therapeutics or any other equity instrument increases or decreases for a given set of returns. It is measured by calculating the standard deviation of the annualized returns over a given period of time and shows the range to which the price of F-Star Therapeutics may increase or decrease. In other words, similar to F-Star's beta indicator, it measures the risk of F-Star Therapeutics and helps estimate the fluctuations that may happen in a short period of time. So if prices of F-Star Therapeutics fluctuate rapidly in a short time span, it is termed to have high volatility, and if it swings slowly in a more extended period, it is understood to have low volatility. Please read more on our technical analysis page.

How F-Star utilizes its cash?

To perform a cash flow analysis of F-Star Therapeutics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash F-Star Therapeutics is receiving and how much cash it distributes out in a given period. The F-Star Therapeutics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. F-Star Therapeutics Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. F-Star Therapeutics reported Net Cash Flow from Operations of (26.15 Million) in 2020

F-Star Therapeutics Gross Profit

F-Star Therapeutics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing F-Star Therapeutics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show F-Star Therapeutics Gross Profit growth over the last 10 years. Please check Gross Profit in more details.

Acquisition by Race Geoffrey of 37 shares of F-Star Therapeutics subject to Rule 16b-3

Legal trades by F-Star Therapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
F-Star insider trading alert for grant of stock option (right to buy) by Race Geoffrey, the corporate stakeholder, on 24th of November 2020. This event was filed by Fstar Therapeutics Inc with SEC on 2020-11-24. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down F-Star Therapeutics Indicators

The current price rise of F-Star Therapeutics could raise concerns from investors as the entity it trading at a share price of 6.99 on 195,900 in volume. The company directors and management may have good odds in positioning the entity resources to exploit market volatility in December. The stock standard deviation of daily returns for 30 days investing horizon is currently 15.76. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the F-Star Therapeutics partners.

Our take on today F-Star Therapeutics rise

Current market risk adjusted performance indicator falls down to -32.96. Possible price jump? F-Star Therapeutics is displaying above-average volatility over the selected time horizon. Investors should scrutinize F-Star Therapeutics independently to ensure intended market timing strategies are aligned with expectations about F-Star Therapeutics volatility.

Our Final Perspective on F-Star Therapeutics

While some other entities under the biotechnology industry are still a bit expensive, F-Star Therapeutics may offer a potential longer-term growth to investors. To conclude, as of the 28th of November 2020, we believe that at this point, F-Star Therapeutics is dangerous with low probability of distress within the next 2 years. From a slightly different point of view, the entity appears to be overvalued. However, our present 30 days buy-or-sell advice on the company is Buy.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of F-Star Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com